ATE543500T1 - Kombinationen mit 5ht6-modulatoren und cholinesterase-hemmern - Google Patents

Kombinationen mit 5ht6-modulatoren und cholinesterase-hemmern

Info

Publication number
ATE543500T1
ATE543500T1 AT07796424T AT07796424T ATE543500T1 AT E543500 T1 ATE543500 T1 AT E543500T1 AT 07796424 T AT07796424 T AT 07796424T AT 07796424 T AT07796424 T AT 07796424T AT E543500 T1 ATE543500 T1 AT E543500T1
Authority
AT
Austria
Prior art keywords
modulators
combinations
cholinesterase inhibitors
cholinesterase
inhibitors
Prior art date
Application number
AT07796424T
Other languages
English (en)
Inventor
Kimberley Gannon
Sharon Shacham
Original Assignee
Galenea Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38611041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE543500(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galenea Corp filed Critical Galenea Corp
Application granted granted Critical
Publication of ATE543500T1 publication Critical patent/ATE543500T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT07796424T 2006-06-26 2007-06-26 Kombinationen mit 5ht6-modulatoren und cholinesterase-hemmern ATE543500T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81651706P 2006-06-26 2006-06-26
PCT/US2007/014747 WO2008002539A1 (en) 2006-06-26 2007-06-26 Combinations comprising 5ht6 modulators and cholinesterase inhibitors

Publications (1)

Publication Number Publication Date
ATE543500T1 true ATE543500T1 (de) 2012-02-15

Family

ID=38611041

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07796424T ATE543500T1 (de) 2006-06-26 2007-06-26 Kombinationen mit 5ht6-modulatoren und cholinesterase-hemmern

Country Status (10)

Country Link
US (1) US20100152141A1 (de)
EP (1) EP2037925B1 (de)
JP (1) JP2009541484A (de)
AR (1) AR061637A1 (de)
AT (1) ATE543500T1 (de)
AU (1) AU2007265515A1 (de)
CA (1) CA2655828A1 (de)
MX (1) MX2008015860A (de)
TW (1) TW200808743A (de)
WO (1) WO2008002539A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488736B2 (en) 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7598265B2 (en) 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
US20090221554A1 (en) * 2008-02-28 2009-09-03 Zenyaku Kogyo Kabushiki Kaisha Method of treating cognitive impairment
US8114894B2 (en) 2008-12-03 2012-02-14 Nanotherapeutics, Inc. Bicyclic compounds and methods of making and using same
US20120010264A1 (en) * 2009-03-26 2012-01-12 Dainippon Sumitomo Pharma Co., Ltd. Novel medicament for treating cognitive impairment
WO2013055386A2 (en) 2011-10-03 2013-04-18 The University Of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
US20160038484A1 (en) * 2013-04-03 2016-02-11 The University Of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
JP2018515607A (ja) * 2015-05-07 2018-06-14 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ 神経変性疾患を処置する組成物および方法
US10864191B2 (en) * 2016-05-11 2020-12-15 H. Lundbeck A/S 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
EA036347B1 (ru) 2016-05-18 2020-10-29 Сувен Лайф Сайенсиз Лимитед Комбинация чистых антагонистов 5-ht6 рецепторов с ингибиторами ацетилхолинэстеразы

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE340795T1 (de) * 2001-01-30 2006-10-15 Lilly Co Eli Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten
WO2005063761A1 (en) * 2003-12-19 2005-07-14 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7968538B2 (en) * 2005-01-25 2011-06-28 Galenea Corp. Substituted arylamine compounds and methods of treatment
PE20071143A1 (es) * 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
ES2358288T3 (es) * 2007-08-01 2011-05-09 Laboratorios Del Dr. Esteve S.A. Combinación de al menos dos ligandos de 5ht6.

Also Published As

Publication number Publication date
EP2037925A1 (de) 2009-03-25
TW200808743A (en) 2008-02-16
AU2007265515A1 (en) 2008-01-03
AR061637A1 (es) 2008-09-10
JP2009541484A (ja) 2009-11-26
WO2008002539A1 (en) 2008-01-03
CA2655828A1 (en) 2008-01-03
EP2037925B1 (de) 2012-02-01
US20100152141A1 (en) 2010-06-17
MX2008015860A (es) 2009-01-30

Similar Documents

Publication Publication Date Title
ATE543500T1 (de) Kombinationen mit 5ht6-modulatoren und cholinesterase-hemmern
FI20075978A0 (fi) Järjestely ja menetelmä
ATE477312T1 (de) Flüssigkeitshärtung
EP2061866A4 (de) Schnelles thermocycler-gerät
BRPI0910925A2 (pt) conjuntos de transferência de líquido e métodos relacionados
EP2047502A4 (de) Nanokristallbildung
ATE479736T1 (de) Cholesterische mehrschichten
EP2087096A4 (de) Modifizierte cyanobakterien
DE602007009238D1 (de) Biplanare elektrode mit sperr-gates
FI20075532A0 (fi) Uusia esteraaseja ja niiden käyttö
DK1989206T3 (da) E1-aktiveringsenzymhæmmere
BRPI0809978A2 (pt) Dispositivos e métodos de dispensação de gotículas
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
DE602007012130D1 (de) Modifizierte flavin-adenin-dinucleotid-abhängige glucose-dehydrogenase
DE602007010066D1 (de) Flüssigkristallanzeige
EP2122054A4 (de) Vliestafel und konstruktionsverfahren dafür
DE602007012419D1 (de) Hochfestes haftpolymergel und klebeband
HRP20141261T1 (xx) Spojevi tioninija i njihove uporabe
NO20090079L (no) Arylsulfonamider med analgesisk virkning
DE602007000495D1 (de) Flüssigkeit-Koinfusionsgerät
FI20065359L (fi) Menetelmä ja rannelaite
EP1841794A4 (de) Adam-9-modulatoren
DE602007004038D1 (de) Flüssigkristallanzeige
CR10430A (es) Aminothiazoles and their uses